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ABSTRACT
Introduction: Diroximel fumarate (DRF) is an
oral fumarate for relapsing multiple sclerosis
(MS) with the same active metabolite as

dimethyl fumarate (DMF). DRF has a safety/efficacy profile similar to DMF but with improved
gastrointestinal (GI) tolerability and low (\ 1%)
treatment discontinuation due to GI adverse
events (AEs). Efficacy and safety outcomes in
patients who switched to DRF from other
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disease-modifying therapies (DMTs) have not
been evaluated.
Methods: EVOLVE-MS-1 is an ongoing, 2-year,
open-label, phase 3 study of DRF in adults with
relapsing–remitting MS. Patients either entered
as newly enrolled to DRF trials, or from the
5-week, randomized, head-to-head, phase 3
EVOLVE-MS-2 study of DRF and DMF. This
analysis evaluated safety and GI tolerability in
patients continuing on DRF (DRF-rollover) or
switching from DMF (DMF-rollover) following
EVOLVE-MS-2. Safety and efficacy were evaluated in a subset of newly enrolled patients who
had received prior glatiramer acetate (GA; GA/
DRF) or interferons (IFN; IFN/DRF) as their most
recent DMT, prior to switching to DRF in
EVOLVE-MS-1.
Results: As of September 1, 2020, 1057 patients
were enrolled in EVOLVE-MS-1, including 166,
182, 239, and 225 patients in the GA/DRF, IFN/
DRF, DRF-rollover, and DMF-rollover groups,
respectively. Treatment discontinuation due to
GI AEs was\ 1% in all groups. GA/DRF and IFN/
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DRF patients experienced improvements from
baseline in clinical and radiological efficacy
outcomes, including significantly reduced
annualized relapse rates. Rollover patients had
low rates of new or recurrent GI AEs (DRF-rollover, 26.8%/4.2%; DMF-rollover, 27.1%/4.9%).
Conclusion: After 2 years of DRF exposure,
patients with prior GA, IFN, or fumarate treatment had safety outcomes consistent with previous fumarate studies. Efficacy in patients with
prior GA or IFN treatment was consistent with
previous fumarate studies. The data suggest that
transition to DRF from GA, IFN, or DMF is a
reasonable treatment strategy, with low rates of
discontinuation due to GI AEs.
Trial Registration: ClinicalTrials.gov (NCT026
34307).

1812

Infographic

Adv Ther (2022) 39:1810–1831

Adv Ther (2022) 39:1810–1831

Keywords: Dimethyl
fumarate;
Diroximel
fumarate;
Efficacy;
Glatiramer
acetate;
Interferon; Multiple sclerosis; Relapsing–
remitting multiple sclerosis; Safety; Tolerability
Key Summary Points
Why carry out this study?
Diroximel fumarate (DRF) previously
demonstrated improved gastrointestinal
(GI) tolerability compared with dimethyl
fumarate (DMF) in the phase 3,
randomized, head-to-head double-blind
EVOLVE-MS-2 trial of patients with
relapsing–remitting multiple sclerosis
(RRMS).
An interim analysis of the ongoing, openlabel, 96-week, phase 3 EVOLVE-MS-1
study of adults with RRMS indicated a low
incidence of GI adverse events (AEs) and a
very low rate of treatment
discontinuation due to GI AEs in the
overall study population, but an analysis
of DRF outcomes following prior diseasemodifying therapy (DMT) has not been
conducted.
The objectives of this analysis were to (1)
assess safety and efficacy outcomes in
patients with RRMS and up to 2 years of
DRF treatment who had received prior
glatiramer acetate (GA) or interferon (IFN)
as their most recent DMT before initiating
DRF in EVOLVE-MS-1, and (2) evaluate GI
tolerability in patients who completed
5 weeks of DRF or DMF treatment in
EVOLVE-MS-2 before initiating DRF in
EVOLVE-MS-1.
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What was learned from the study?
Safety outcomes in patients who switch to
DRF treatment were consistent with what
has been reported for the overall
population: AEs were generally mild or
moderate in severity and led to treatment
discontinuation at an overall similar rate
among all analysis groups; absolute
lymphocyte count decreased by approx.
30% over the first year of treatment with
DRF and then stabilized to a level greater
than the lower limit of normal for the
majority of patients consistent with other
DMF studies.
Patients treated with DRF over 2 years
experienced improvements on clinical
and radiological efficacy relative to those
reported for the preceding treatment
period with IFN and GA. Adjusted
annualized relapse rate was significantly
reduced (p \ 0.0001 for both prior IFN
and prior GA groups) after up to 2 years of
DRF treatment compared with the
reported annualized relapse rate in the
12 months before fumarate initiation.
Patients with prior DMF or DRF treatment
for 5 weeks in EVOLVE-MS-2 had low rates
of new or recurring GI AEs after initiating
DRF in the 2-year EVOLVE-MS-1 study,
and the rate of treatment discontinuation
due to GI AEs across both groups (prior
DMF or prior DRF) was \ 1%. The data
suggest that transition from DMF to DRF,
which have the same active metabolite, is
a reasonable treatment strategy for
appropriate patients with RRMS.
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DIGITAL FEATURES
This article is published with digital features,
including an infographic, to facilitate understanding of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.19086380.

INTRODUCTION
Over 20 disease-modifying therapies (DMTs) are
currently available for the treatment of relapsing multiple sclerosis (MS), including injectable,
infused, and oral medications [1]. Glatiramer
acetate (GA) and interferon-beta (IFNb)-1a/b
(including IFNb1a subcutaneous [SC], IFNb1a
intramuscular [IM], peginterferon-b1a [SC or
IM], and IFNb1b [SC]) are injectable DMTs that
serve as common first-line treatment options for
patients with MS, in addition to oral therapies
such as dimethyl fumarate (DMF) and diroximel
fumarate (DRF) [2–7]. Injectable therapies have
been shown to reduce relapse rates and number
of new magnetic resonance imaging (MRI)
lesions in patients with MS [3–6]. Although no
direct head-to-head comparisons have been
performed between IFN, GA, and DMF, comparative effectiveness studies utilizing propensity score methodology indicate that the
effectiveness of injectable therapies is slightly
lower than that of DMF, as shown by reduced
annualized relapse rate (ARR) with DMF treatment compared with injectable treatments
[8, 9]. Some patients treated with an
injectable therapy discontinue or switch therapies because of tolerability issues such as injection site reactions and flu-like symptoms, lack
of efficacy, safety concerns, or overall treatment
burden [2, 10–12]. Some patients taking DMF
experience gastrointestinal (GI) adverse events
(AEs) initially, and sometimes throughout
treatment, that may lead to dose interruption or
discontinuation [13, 14].
DRF is a next-generation oral fumarate
approved for the treatment of patients with
relapsing forms of MS [15]. Oral administration
of DRF leads to rapid conversion to
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monomethyl fumarate (MMF), the same pharmacologically active metabolite as DMF. It has
been demonstrated that 462 mg of DRF results
in MMF systemic exposure that is bioequivalent
to 240 mg DMF (Supplementary Material) [16].
Therefore, DRF and DMF have similar efficacy
and safety profiles. DMF has demonstrated a
favorable benefit–risk profile in clinical and realworld studies of patients with MS [17–21]. As of
June 30, 2021, more than 537,000 patients have
received DMF, representing more than
1,100,000 patient years of exposure. DRF
demonstrated improved GI tolerability compared with DMF in the phase 3, randomized,
head-to-head, double-blind, 5-week EVOLVEMS-2 trial [22]. Prior studies of DMF have indicated that the incidence of GI events is highest
in the first month of treatment [23], so the
5-week treatment period was a suitable time
period for assessing these outcomes. Patients
who completed the 5-week treatment period in
EVOLVE-MS-2 were eligible to roll over into
EVOLVE-MS-1, an ongoing single-arm, openlabel study to evaluate safety, tolerability, and
efficacy of DRF over 96 weeks.
Evaluation of DRF safety and efficacy in
patients who transition from GA or IFN, and
DRF GI tolerability in patients who transition
from DMF, may help inform clinical practice
and sequencing options. In this analysis, the
safety and efficacy of DRF in patients who
switched to DRF from other DMTs, specifically
IFN or GA in the EVOLVE-MS-1 study, was
assessed. GI tolerability was also evaluated for
patients treated with DRF in the EVOLVE-MS-1
study, which was compared with GI tolerability
when they were treated with DMF in the 5-week
EVOLVE-MS-2 study.
The objectives of this analysis were to (1)
assess safety, efficacy, and tolerability outcomes
in patients with up to 2 years of DRF treatment
who had received prior GA or IFN as their most
recent DMT before initiating DRF in EVOLVEMS-1, and (2) evaluate GI tolerability in patients
who completed 5 weeks of DMF to DRF treatment in the EVOLVE-MS-2 study before rolling
over to EVOLVE-MS-1.
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METHODS
Study Design and Patients
EVOLVE-MS-1 (NCT02634307) is an ongoing,
open-label, phase 3 study assessing safety, tolerability, and efficacy of DRF over 96 weeks in
adults with relapsing–remitting MS (RRMS). The
study design, DRF dosing regimen, patient
population, and study endpoints have been
previously described [16]. In brief, patients
entered the study either as newly enrolled to the
DRF clinical development program or after
completing EVOLVE-MS-2 (NCT03093324), a
randomized, double-blind, phase 3 study in
which patients received DRF or DMF over
5 weeks. Rollover patients from EVOLVE-MS-2
either continued on DRF (DRF-rollover) or
switched from DMF to DRF (DMF-rollover).
DRF was administered orally as 462 mg twice
daily. For patients newly enrolled to the DRF
studies, the dose was titrated as 231 mg twice
daily for the first study week, followed by
462 mg twice daily thereafter.
Eligible patients were 18–65 years of age with
a confirmed diagnosis of RRMS [24], had no
history of clinically significant recurring or
active GI symptoms within 3 months of
screening, and were neurologically stable with
no evidence of relapse within 30 days before
screening. Rollover patients had already met the
EVOLVE-MS-2 study criteria and rolled over
into EVOLVE-MS-1. Complete eligibility criteria
have been previously described [16].
The study protocol was reviewed and
approved by the Copernicus Group institutional
review board and the institutional review board/
independent ethics committee for each study
site (Supplementary Material) before enrolling
patients and releasing drug to investigators. The
study was conducted in accordance with the
protocol, the International Council for Harmonization Guideline E6, all applicable local regulatory requirements, and ethical principles based
on the Declaration of Helsinki. All patients provided their written informed consent before
participating in the study.
This study evaluated safety and efficacy in a
subgroup of patients from EVOLVE-MS-1 who
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had previously received GA or IFN as their most
recent DMT (GA/DRF and IFN/DRF groups,
respectively) before switching to DRF when
enrolling in EVOLVE-MS-1. The timing of discontinuing prior GA or IFN before initiating
DRF was at the patient’s and investigator’s discretion; no defined washout period was included. The subgroup analysis for GI tolerability
was performed in rollover patients, defined as
those who had completed 5 weeks of DRF or
DMF treatment during the EVOLVE-MS-2 study
(DRF-rollover and DMF-rollover groups, respectively) before starting EVOLVE-MS-1. The
EVOLVE-MS-1 treatment period began at the
time of or within 7 days of the EVOLVE-MS-2
end of treatment visit.
Endpoints Included in the Analysis
Safety and tolerability were assessed in all
patients included in the analysis. Assessments
included number and percentage of treatmentemergent AEs, GI AEs, serious adverse events
(SAEs), and AEs leading to treatment discontinuation. AEs were monitored by the investigator at each study visit and coded using the
Medical Dictionary for Regulatory Activities
(MedDRA) system organ class and preferred
term. GI AEs were defined according to the
MedDRA system organ class for GI disorders. A
complete blood count, including absolute lymphocyte count (ALC), was assessed at each study
visit. ALCs were graded according to the Common Terminology Criteria for Adverse Events
(CTCAE v4.0) as follows: grade 0 (C lower limit
of normal [LLN] [C 910 mm3]); grade 1 (\ LLN
to C 800 mm3); grade 2 (\ 800–500 mm3);
grade 3
(\ 500–200 mm3);
and
grade 4
(\ 200 mm3); ALC LLN was defined as
\ 0.91 9 109/L [16, 25, 26].
Efficacy outcomes were assessed in the GA/
DRF and IFN/DRF groups relative to the outcomes reported for the prior treatment on GA
and IFN, including ARR, proportion of patients
free from relapse, proportion free from confirmed disability progression (CDP), proportion
with confirmed disability improvement (CDI),
proportion with no evidence of disease activity
(NEDA)-3, patient-reported outcomes (PROs),
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and MRI outcomes—number of gadoliniumenhancing (Gd?) lesions, percentage of patients
free from Gd? lesions, percentage brain volume
change (PBVC), and number of new or enlarging T2 lesions.
On-study relapse endpoints were based on
the number of protocol-defined relapses,
defined as new or recurrent neurologic symptoms, not associated with fever or infection,
lasting for at least 24 h and accompanied by
new neurological findings reflected in a change
in Expanded Disability Status Scale (EDSS) score.
Pre-study relapse endpoints were based on
patient-reported number of relapses in the
12 months before study enrollment, collected at
baseline. CDP was based on EDSS score and
defined as a C 1.5-point increase from a baseline
score of 0.0, a C 1.0-point increase from a
baseline score of 1.0 to \ 6.0, or a C 0.5-point
increase from a baseline score of C 6.0, confirmed 12 weeks later. CDI was defined as a
C 1.0-point decrease in EDSS score from a
baseline EDSS score C 2.0, confirmed 12 weeks
later. CDI was not assessed in patients with a
baseline EDSS score of \ 2.0. NEDA-3 was
defined as no relapses, no CDP sustained for
12 weeks as measured on EDSS, no new or
enlarging T2 hyperintense lesions, and no new
Gd? lesions, during the 96-week trial duration.
Brain MRI scans were performed with and
without gadolinium utilizing a standardized
sequence under the supervision by the MRI
reading center (NeuroRx Research, Montreal,
QC, Canada). MRIs were obtained at baseline,
48 weeks, 96 weeks, or at study termination.
MRI scans included the following sequence:
PD-, T1, and T2-weighted 2D multislice (precontrast), T1-weighted 3D spoiled gradient
recalled echo (pre-contrast), 2D T2-weighted
FLAIR, and 3D spoiled gradient-recalled echo
T1-weighted (postcontrast). For assessment of
brain atrophy, PBVC was calculated automatically for week 48 and 96 relative to normalized
brain volume at baseline. For the PBVC, the
type and length of format was BEST 6.2 and the
units were percentages in a SAS Dataset format
for visits at week 48, 96, and end of study. PROs
were assessed using the 12-item Short-Form
health survey (SF-12) and the 5-level EuroQol5d group health outcome measure (EQ-5D-5L).

DRF treatment adherence was assessed in all
patients and was reported as a percentage, calculated as the number of capsules taken divided
by the number of capsules expected to be taken,
multiplied by 100.
A GI tolerability analysis was conducted in
DRF- and DMF-rollover patients. Analysis of GI
tolerability assessments included onset of new
GI AEs, recurrence of prior GI AEs, and GI-related treatment discontinuations.
Statistics
Safety and tolerability assessments were conducted in patients who received at least one
dose of DRF and summarized using descriptive
statistics. MS relapse rate was assessed in
patients with prior GA or IFN treatment who
received at least one dose of DRF. Adjusted ARR
was based on a Poisson regression model
adjusted for study period. Adjusted ARR included protocol-defined relapses that occurred
during the EVOLVE-MS-1 treatment period (up
to 2 years of DRF). Rates were compared with
the reported relapse rate for the 12 months
before DRF initiation in EVOLVE-MS-1 for GA/
DRF and IFN/DRF groups. CDP and MRI outcomes were assessed in patients who received at
least one dose of DRF and completed at least
one post-baseline efficacy assessment. The estimated proportion of patients free from relapse
and free from CDP was based on the Kaplan–Meier product limit method. The estimated
proportion of patients with CDI was based on
the Kaplan–Meier product limit method and
only included patients with a baseline EDSS
C 2.0. The estimated proportion of patients
with NEDA-3 was based on the Kaplan–Meier
product limit method using relapse, MRI, EDSS
data, and based on the number of evaluable
patients for NEDA-3.
Gd? lesion count, new or enlarging T2 lesion
count, and PBVC were summarized by time
point and change from baseline using descriptive statistics. Changes in SF-12 mental and
physical component scale scores and EQ-5D-5L
index and visual analog scale (VAS) scores from
baseline to year 2 were summarized by prior
treatment group.
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RESULTS
Patients
A total of 1057 patients were enrolled in
EVOLVE-MS-1 as of September 1, 2020. This
switch subgroup analysis included 166 patients
who had received GA (GA/DRF) and 182
patients who had received IFN (IFN/DRF) as
their most recent prior DMT before being treated with DRF in EVOLVE-MS-1. In the GI tolerability subgroup analysis, 239 patients
previously treated with DRF in EVOLVE-MS-2
(DRF-rollover) and 225 previously treated with
DMF in EVOLVE-MS-2 (DMF-rollover) before
being treated with DRF in EVOLVE-MS-1 were
included.
As of September 2020, 87% (916/1057) of
patients completed the 2-year study. Of the
patients in the GA/DRF and IFN/DRF groups,
57% (94/166) and 59% (108/182) completed the
2-year study, respectively, and 33% (55/166)
and 30% (54/182) discontinued treatment at

Fig. 1 Patient disposition. aIncludes pregnancy, physician
decision, lack of efﬁcacy, noncompliance with study drug,
or other reason. Of the patients enrolled in EVOLVE-MS1, only those who were previously treated with IFN or GA,
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the time of the analysis, respectively (Fig. 1). Of
the patients in the DRF-rollover and DMF-rollover groups, 40.2% (96/239) and 42.2% (95/
225) had completed the study, respectively, and
26.4% (63/239) and 25.8% (58/225) had discontinued treatment, respectively.
Baseline characteristics were generally similar among all analysis groups, although patients
switching from IFN had a slightly longer time
since diagnosis than those from the other
analysis groups (Table 1). Patients in the GA/
DRF and IFN/DRF groups received prior GA or
IFN for a median (interquartile range [IQR])
treatment duration of 1.76 (0.82–3.55) and 2.80
(0.86–5.58) years, respectively, before initiating
DRF in EVOLVE-MS-1. Patients in the DRF-rollover and DMF-rollover groups had received DRF
or DMF for 5 weeks as mandated by the
EVOLVE-MS-2 protocol before initiating DRF in
EVOLVE-MS-1.
At the time of this analysis, median (range)
duration of DRF treatment was 1.8 (0.0–1.9)
years for the GA/DRF and IFN/DRF groups and

or who rolled over from the completed EVOLVE-MS-2
study were included in this analysis. AE adverse event,
DMF dimethyl fumarate, DRF diroximel fumarate, GA
glatiramer acetate, IFN interferon

Adv Ther (2022) 39:1810–1831
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Table 1 Baseline demographics and disease characteristics in EVOLVE-MS-1 patients who received DMF, GA, or IFN as
their most recent DMT before initiating DRF
GA/DRF
n = 166

IFN/DRF
n = 182

EVOLVE-MS-2
rolloversa
DRFrollover
n = 239

DMFrollover
n = 225

Mean (SD) age, years

44.0 (10.4)

43.9 (10.5)

44.0 (11.0)

43.7 (9.8)

Female, n (%)

124 (75)

137 (75)

165 (69)

170 (76)

White

151 (91)

158 (87)

220 (92)

205 (91)

Black or African American

13 (8)

21 (12)

19 (8)

16 (7)

Other

2 (1)

3 (2)

0

4 (2)

28.8 (6.5)

27.1 (6.4)

27.0 (5.9)

27.6 (6.2)

117 (71)

102 (56)

124 (52)

121 (54)

Treatment duration of most recent prior DMT,
years (IQR)

GA, 1.76
(0.82–3.55)

IFN, 2.80
(0.86–5.58)

N/Ab

N/Ab

Mean (SD) time since diagnosis, years

8.2 (7.2)

9.6 (7.0)

7.4 (7.8)

7.8 (7.5)

Mean (SD) number of relapses in previous year

0.6 (0.7)

0.5 (0.7)

0.6 (0.7)

0.6 (0.7)

Mean (SD) EDSS score

2.6 (1.5)

2.5 (1.5)

2.6 (1.5)

2.7 (1.4)

Mean (SD) number of Gd lesions

0.7 (2.5)

0.8 (2.4)

0.8 (2.2)

0.9 (2.6)

Gd? lesion-free, n (%)

128 (77)

143 (79)

176 (74)

159 (71)

Race, n (%)

Mean (SD) BMI, kg/m2
US region, n (%)

?

AE adverse event, BMI body mass index, DMF dimethyl fumarate, DMT disease-modifying therapy, DRF diroximel
fumarate, EDSS Expanded Disability Status Scale, GA glatiramer acetate, Gd? gadolinium-enhancing, IFN interferon, IQR
interquartile range
a
For patients who completed EVOLVE-MS-2 before enrolling in EVOLVE-MS-1, MRI data were collected at EVOLVEMS-1 baseline; all other baseline characteristics data were collected during the antecedent study (EVOLVE-MS-2)
b
Patients received 5 weeks of DRF or DMF treatment in the EVOLVE-MS-2 study before starting EVOLVE-MS-1; 66.8%
of DRF/DRF patients and 66.1% of DMF/DRF patients received C 1 prior DMT before enrolling in EVOLVE-MS-2
1.6 (0.0–1.9) years for the DRF-rollover and
DMF-rollover groups. Mean (standard deviation
[SD]) treatment adherence with DRF was above
93% for all groups: GA/DRF 93.1% (11.6), IFN/
DRF 94.5% (9.9), DRF-rollover 95.0% (9.1), and
DMF-rollover 95.4% (7.7).
Safety
Safety Summary
The percentage of patients with any treatmentemergent AE was similar across all analysis

groups: GA/DRF, 92.8%; IFN/DRF, 88.5% DRFrollover, 87.9%; DMF-rollover, 90.2% (Table 2).
AEs were mild or moderate in severity for most
patients. The most common AEs in patients
with GA/DRF or IFN/DRF treatment were
flushing (32.5% and 33.0%), MS relapse (23.5%
and 15.9%), upper respiratory tract infection
(15.1% and 16.5%), and diarrhea (15.1% and
11.0%), respectively (Table 3). The most common AEs in patients with prior fumarate exposure in the DRF-rollover and DMF-rollover
groups, respectively, were MS relapse (19.2%

Adv Ther (2022) 39:1810–1831
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Table 2 Summary of safety
GA/DRF
n = 166

IFN/DRF
n = 182

EVOLVE-MS-2 rollovers
DRF-rollover
n = 239

DMF-rollover
n = 225

Any AE

154 (92.8)

161 (88.5)

210 (87.9)

203 (90.2)

Mild

52 (31.3)

42 (23.1)

66 (27.6)

71 (31.6)

Moderate

88 (53.0)

103 (56.6)

121 (50.6)

109 (48.4)

Severe

14 (8.4)

16 (8.8)

23 (9.6)

23 (10.2)

58 (34.9)

69 (37.9)

70 (29.3)

64 (28.4)

Diarrhea

25 (15.1)

20 (11.0)

18 (7.5)

25 (11.1)

Nausea

20 (12.0)

12 (6.6)

12 (5.0)

15 (6.7)

Constipation

6 (3.6)

13 (7.1)

9 (3.8)

12 (5.3)

Upper abdominal pain

6 (3.6)

11 (6.0)

5 (2.1)

4 (1.8)

Vomiting

4 (2.4)

10 (5.5)

7 (2.9)

10 (4.4)

83 (50.0)

89 (48.9)

108 (45.2)

119 (52.9)

Serious infections

2 (1.2)

1 (0.5)

2 (0.8)

2 (0.9)

Opportunistic Infections

3 (1.8)

1 (0.5)

2 (0.8)

1 (0.4)

2 (1.2)

0

1 (0.4)

0

0

1 (0.5)

0

1 (0.4)

Vulvovaginal candidiasis

1 (0.6)

0

1 (0.4)

0

Esophageal candidiasis

0

1 (0.5)

0

1 (0.4)

0

1 (0.5)

0

2 (0.9)

19 (11.4)

19 (10.4)

23 (9.6)

13 (5.8)

0

1 (0.5)

1 (0.4)

1 (0.4)

20 (12.0)

18 (9.9)

28 (11.7)

23 (10.2)

0

0

1 (0.4)

0

GI AEs (occurring in C 5% of patients in any group)

Infections

Oral candidiasis
Candida infection

COVID-19
AEs leading to treatment discontinuation
GI AEs leading to treatment discontinuation
SAEs

a,b,c,d

Death

e

AE adverse event, DMF dimethyl fumarate, DRF diroximel fumarate, GA glatiramer acetate, GI gastrointestinal, IFN interferon, SAE serious AE
SAEs in the DRF-rollover group included MS relapse, n = 19; and 1 patient each with gastritis; inguinal hernia; chronic gastritis; eosinophilic
esophagitis; appendicitis; pharyngitis; cardiac arrest; stress cardiomyopathy; parathyroid tumor benign; endometrial hyperplasia; vaginal prolapse;
cholecystitis; cholelithiasis; alanine aminotransferase increased; pyrexia. Some patients may have experienced more than 1 SAE
b
SAEs in the DMF-rollover group included MS relapse, n = 10; abdominal pain, n = 2; and 1 patient each with cerebellar embolism; idiopathic
intracranial hypertension; seizure; gastritis; vomiting; fall; accidental overdose; joint injury; cellulitis; urinary tract infection; myocardial infarction;
benign neoplasm of bladder; diffuse large B cell lymphoma; cholecystitis; cholestatic liver injury; back pain; ﬂank pain; bipolar I disorder; pulmonary
embolism; Leriche syndrome; chorioretinopathy. Some patients may have experienced more than 1 SAE
c
SAEs in the GA/DRF group included MS relapse, n = 7; and 1 patient each with uterine leiomyoma; fallopian tube cyst; abortion spontaneous; cardiac
failure; diffuse large B cell lymphoma; sepsis; cellulitis; suicidal ideation; pelvic prolapse; sciatica; cholelithiasis; chorioretinopathy; bipolar I disorder
d
SAEs in the IFN/DRF group included MS relapse, n = 7; MS relapse, cholecystitis, abdominal pain, fall, vomiting, back pain, ﬂank pain, accidental
overdose, n = 1; and 1 patient each with stress cardiomyopathy; abdominal pain; pneumonia and respiratory failure; invasive ductal breast carcinoma;
road trafﬁc accident; lower limb fracture; seizure; liver function test increased; suicidal ideation; osteonecrosis; spontaneous abortion
e
Due to cardiac arrest that was probably not related to study drug
a
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Table 3 Most common AEs (occurring in at least 10% of patients in any group)
AE, n (%)

GA/DRF
n = 166

IFN/DRF
n = 182

EVOLVE-MS-2 rollovers
DRF-rollover
n = 239

DMF-rollover
n = 225

MS relapse

39 (24)

29 (16)

46 (19)

42 (19)

Upper respiratory tract infection

25 (15)

30 (17)

40 (17)

35 (16)

Flushing

54 (33)

60 (33)

33 (14)

29 (13)

Lymphopenia

13 (8)

22 (12)

33 (14)

34 (15)

Fatigue

16 (10)

13 (7)

26 (11)

22 (10)

Nasopharyngitis

21 (13)

20 (11)

24 (10)

26 (12)

Urinary tract infection

19 (11)

24 (13)

23 (10)

24 (11)

Headache

11 (7)

14 (8)

22 (9)

23 (10)

Diarrhea

25 (15)

20 (11)

18 (8)

25 (11)

Nausea

20 (12)

12 (7)

12 (5)

15 (7)

Pruritis

22 (13)

13 (7)

8 (3)

10 (4)

AE adverse event, DMF dimethyl fumarate, DRF diroximel fumarate, GA glatiramer acetate, IFN interferon, MS multiple
sclerosis

and 18.7%), upper respiratory tract infection
(16.7% and 15.6%), lymphopenia (13.8% and
15.1%), and flushing (13.8% and 12.9%). Rollover patients had a lower incidence of GI AEs
(DRF-rollover, 29.3% [70/239]; DMF-rollover,
28.4% [64/225]) compared with patients whose
most recent DMT was not a fumarate (GA/DRF,
34.9%; IFN/DRF, 37.9%).
Infection was reported by approximately
50% of patients, including 50.0%, 48.9%,
45.2%, and 52.9% of GA/DRF, IFN/DRF, DRFrollover, and DMF-rollover patients, respectively (Table 2). Rates of serious infections,
opportunistic infections (Candida infections),
and confirmed/suspected COVID-19 were at
most 1% across all patient groups.
AEs led to discontinuation of study drug in
11.4% of GA/DRF and 10.4% of IFN/DRF
patients. Rates were slightly lower in rollover
patients: 9.6% DRF-rollover, 5.8% DMF-rollover. GI AEs resulted in treatment discontinuation in three of the 811 patients (\ 1%) across
all groups: IFN/DRF, n = 1; DRF-rollover, n = 1;
DMF-rollover, n = 1. Flushing resulted in

treatment discontinuation in six of the 811
patients (\ 1%) across all groups: GA/DRF,
n = 2; IFN/DRF, n = 1; DRF-rollover, n = 2; DMFrollover, n = 1.
Change in Absolute Lymphocyte Count
Across all analysis groups, ALC declined by
approximately 30% over the first year of treatment (GA/DRF, 31.7%; IFN/DRF, 27.1%; DRFrollover, 29.0%; DMF-rollover, 30.2%) and then
stabilized to a level above the LLN (Fig. 2) for
the majority of patients in all groups: GA/DRF
57.0% (94/165), IFN/DRF 52.8% (93/176), DRFrollover 58.8% (140/238), DMF-rollover 60.4%
(136/225). Approximately 10% of patients
experienced at least one ALC \ 0.5 9 109/L:
10.3% (17/165) in the GA/DRF; 12.5% (22/176)
in the IFN/DRF; 10.5% (25/238) in the DRFrollover; and 9.3% (21/225) in the DMF-rollover
groups. The protocol stopping rule was patients
who had a lymphocyte count \ 0.5 9 109/L
had to temporarily discontinue and if the ALC
remained \ 0.5 9 109/L then the subject must
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Fig. 2 Change in ALC over time. aPatients in the DRFrollover and DMF-rollover groups received 5 weeks of
DRF or DMF treatment before EVOLVE-MS-1 enrollment. ALC absolute lymphocyte count, DMF dimethyl

fumarate, DRF diroximel fumarate, LLN lower limit of
normal

permanently discontinue; therefore, the number of patients with severe prolonged
([ 6 months) lymphopenia was not assessed.
Efficacy

The estimated proportion of patients with
NEDA-3 at week 48 and week 96 (over the full
96-week treatment period) was GA/DRF, 63.0%
and 39.9%; and IFN/DRF, 69.9% and 45.8%,
respectively (Fig. 4).

Clinical Efficacy in Patients Initiating DRF
After Prior GA or IFN Treatment
Adjusted ARR was significantly reduced (GA/
DRF 74.0% [rate ratio 0.26, 95% confidence
interval 0.18, 0.38] and IFN/DRF 78.7% [rate
ratio 0.21, 95% confidence interval 0.14, 0.31];
p \ 0.0001 for both) during the EVOLVE-MS-1
treatment period (DRF for up to 2 years) compared with the 12 months before treatment
with DRF (Fig. 3). The estimated proportion of
patients in the GA/DRF and IFN/DRF groups
who were free from relapse at week 96 was
78.4% and 85.5%, respectively. The estimated
proportion of patients who were free from CDP
at week 96 was 84.9% and 87.4%, respectively.
The estimated proportion of patients with CDI
at week 96 was 16.3% and 10.3%, respectively.

Radiological Efficacy in Patients Initiating
DRF After Prior GA or IFN Treatment
For all analysis groups, mean number of Gd?
lesions decreased over the 2-year treatment
period relative to prior GA or IFN treatment
(GA/DRF and IFN/DRF groups) (Fig. 5a). The
percentage of patients free from Gd? lesions
increased from the relative baseline to year 2
in the GA/DRF (from 78.8% to 96.0%) and
IFN/DRF groups (from 80.2% to 92.8%;
Fig. 5b). Mean (SD) number of new or
enlarging T2 lesions from the relative baseline to year 1 and from year 1 to year 2 was
1.0 (2.5) and 0.3 (1.4), respectively, in the
GA/DRF; and 1.7 (6.6) and 1.3 (6.0), respectively, in the IFN/DRF groups. Mean (SD)
PBVC from year 1 to year 2 was - 0.2 (0.6) in
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Fig. 3 Adjusted ARR on DRF treatment compared with
the 12 months before DRF or DMF initiation in GA/
DRF and IFN/DRF treatment groups: adjusted ARR for
protocol-deﬁned relapses during the EVOLVE-MS-1
treatment period (up to 2 years of DRF treatment)

Adv Ther (2022) 39:1810–1831

compared with patient-reported relapses in the 12 months
before DRF initiation in EVOLVE-MS-1. ARR annualized
relapse rate, DRF diroximel fumarate, GA glatiramer
acetate, IFN interferon

Fig. 4 Estimated proportion of patients with NEDA-3 after 1 or 2 years of DRF treatment in EVOLVE-MS-1. DRF
diroximel fumarate, GA glatiramer acetate, IFN interferon, NEDA-3 no evidence of disease activity-3
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Fig. 5 a Mean (SE) number of Gd? lesions and b percentage of patients free from Gd? lesions. DRF diroximel fumarate,
GA glatiramer acetate, Gd? gadolinium-enhancing, IFN interferon
the GA/DRF group; and - 0.3 (0.6) in the
IFN/DRF group (Fig. 6).

GI Tolerability in EVOLVE-MS-2 Rollover
Patients

Patient-Reported Outcomes

A total of 33.9% (81/239) and 44.9% (101/225)
of patients in the DRF-rollover and DMF-rollover groups, respectively, had a prior GI AE in
EVOLVE-MS-2 (Table 5). Most of these AEs were
mild or moderate in severity (96.3% [78/81] and
97.0% [98/101], respectively). The events had
resolved in 77.8% (63/81) and 78.2% (79/101)

SF-12 mental and physical component scores
and EQ-5D index and VAS scores remained
stable over the 2-year treatment period for both
GA/DRF and IFN/DRF groups (Table 4).
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Fig. 6 Mean (SE) PBVC from year 1 to year 2a in
EVOLVE-MS-1. aPBVC from baseline to year 1 is not
reported to avoid confounding by pseudo-atrophy.

Estimated yearly brain volume loss in healthy adults
[35]. DRF diroximel fumarate, GA glatiramer acetate, IFN
interferon, PBVC percentage brain volume change

of patients, respectively; GI AEs that resolved in
EVOLVE-MS-2 were unlikely to reoccur in the
EVOLVE-MS-1 extension study (DRF-rollover,
4.2%; DMF-rollover, 4.9%). Onset of new GI AEs
(the report of a GI AE not previously reported in
the EVOLVE-MS-2 study) in EVOLVE-MS-1 was
26.8% in the DRF-rollover group and 27.1% in
the DMF-rollover group. Most were mild or
moderate in severity (93.8% [60/64] and 91.8%
[56/61], respectively).
Overall, the rates of GI AEs in EVOLVE-MS-1
were 29.3% (70/239) and 28.4% (64/225) for
DRF-rollover and DMF-rollover patients,
respectively. The majority of events were mild
or moderate in severity: DRF-rollover, 94.3%
(66/70); DMF-rollover 90.6% (58/64). Patients
in the DMF-rollover group had a slightly higher
incidence of diarrhea (DMF-rollover 11.1% vs
DRF-rollover 7.5%), nausea (DMF-rollover 6.7%
vs DRF-rollover 5.0%), constipation (DMF-rollover 5.3% vs DRF-rollover 3.8%), and vomiting
(DMF-rollover 4.4% vs DRF-rollover 2.9%)
compared with patients in the DRF-rollover
group. Fewer than 1% of all patients with GI AEs
in EVOLVE-MS-2 discontinued treatment
because of GI AEs in EVOLVE-MS-1 (Table 6).

DISCUSSION

b

Patients with up to 2 years of DRF treatment
who had rolled over from EVOLVE-MS-2 or had
received GA or IFN as their most recent DMT
before study enrollment had overall safety outcomes that were consistent with previous studies of DRF [16, 22], and there were no
unexpected safety concerns. For patients who
received GA or IFN as their most recent DMT
(GA/DRF and IFN/DRF groups), significant
improvements in ARR were observed on DRF for
up to 2 years compared with the 12 months
before treatment with DRF (p \ 0.0001 for
both). Improvements in other clinical and
radiological measures of disease activity were
observed on DRF, but were not found to be
statistically significant. Thus, the findings in
this study support previous studies demonstrating that oral fumarates may be an effective
treatment option for patients switching from
GA or IFNs [11, 21, 27].
AEs were generally mild or moderate in
severity and led to treatment discontinuation at
an overall similar rate among patients in this
analysis and the overall study population [16].
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Table 4 Summary of patient-reported outcomes
PRO, mean (SD)

GA/DRF

IFN/DRF

Patients, n (%)

SF-12a
MCS score, BL

49.87 (10.51);
n = 166

50.32 (9.30);
n = 174

MCS score, Y2

47.10 (10.49);
n = 99

48.01 (10.19);
n = 113

MCS, change from
BL to Y2
PCS score, BL
PCS, Y2
PCS, change from
BL to Y2

- 1.87 (10.34)
43.87 (11.04);
n = 166

44.38 (9.71);
n = 174

43.22 (11.10);
n = 99

45.39 (10.61);
n = 113

- 0.32 (7.18)

0.35 (6.65)

Index score, Y2
Index, change from
BL to Y2

EVOLVE-MS-2
rollovers
DRFDMFrollover rollover
n = 239 n = 225

Any GI AE in EVOLVE-MS-2

81
(33.9)

101
(44.9)

Mild

62
(25.9)

70 (31.1)

Moderate

16 (6.7)

28 (12.4)

Severe

3 (1.3)

3 (1.3)

- 2.90 (8.91)

EQ-5D-5La
Index score, BL

Table 5 GI tolerability in patients who received DMF or
DRF in EVOLVE-MS-2

GI AE in EVOLVE-MS-1 that had 10 (4.2)
previously occurred and resolved
in EVOLVE-MS-2

11 (4.9)

New GI AE in EVOLVE-MS-1

64
(26.8)

61 (27.1)

0.83 (0.13);
n = 163

0.83 (0.13);
n = 174

Mild

29 (12.9)

0.78 (0.16);
n = 100

0.80 (0.17);
n = 113

35
(14.6)

Moderate

25
(10.5)

27 (12.0)

Severe

4 (1.7)

5 (2.2)

70
(29.3)

64 (28.4)

- 0.03 (0.11)

- 0.04 (0.12)

VAS score, BL

78.4 (17.69);
n = 163

78.0 (17.02);
n = 174

Any GI AE in EVOLVE-MS-1

VAS score, Y2

74.1 (19.64);
n = 100

77.3 (18.09);
n = 113

AE adverse event, DMF dimethyl fumarate, DRF diroximel fumarate, GI gastrointestinal

VAS, change from
BL to Y2

- 3.1 (16.23)

- 1.9 (13.61)

BL baseline, EQ-5D-5L EuroQol Group Health Outcome
Measures 5-Level Version, MCS mental component summary, PCS physical component summary, SF-12 12-item
Short-Form healthy survey, Version 2, VAS visual analog
scale, Y2 year 2
a
Higher scores indicate better health

GI AEs and flushing both occurred at slightly
higher rates in patients with no prior fumarate
exposure compared with patients who received
5 weeks of DRF or DMF in EVOLVE-MS-2. This
finding is not unexpected given that GI AEs and

flushing are known to occur early in treatment,
typically within 1 month of DRF or DMF initiation and decrease over time [13, 16]. Therefore,
patients with prior fumarate exposure who may
have been susceptible to flushing and GI AEs
likely experienced the majority of those events
during the earlier EVOLVE-MS-2 study.
An approximately 30% decline in ALC was
observed over the first year of treatment across
all treatment groups and plateaued over time.
This change in ALC was also observed in the
phase 3 and extension studies for DMF [23], and
was previously observed with DRF in the overall
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Table 6 Disposition of patients with GI AEs in EVOLVE-MS-2 who rolled over into EVOLVE-MS-1
Patients, n (%)

EVOLVE-MS-2 rollovers
DRF-rollover
n = 239

DMF-rollover
n = 225

Any GI AE in EVOLVE-MS-2

81 (33.9)

101 (44.9)

Ongoing in EVOLVE-MS-1

26 (10.9)

26 (11.6)

Discontinued treatment in EVOLVE-MS-1

19 (7.9)

30 (13.3)

0

1 (0.4)

36 (15.1)

45 (20.0)

Discontinued EVOLVE-MS-1 because of GI AE
Completed treatment in EVOLVE-MS-1

AE adverse event, DMF dimethyl fumarate, DRF diroximel fumarate, GI gastrointestinal

population of EVOLVE-MS-1 [16]. Despite the
decline in ALC, previous studies have reported
an intact humoral immune response in DMFtreated patients with RRMS, as demonstrated by
the immune response (recall antigen, T cell-independent antigen, and neoantigen) to vaccination that provided adequate seroprotection
[28], and stable levels of immunoglobulins (IgA,
IgG, and IgM) over 2 years of therapy regardless
of ALCs [29]. These findings are consistent with
long-term safety data that show no overall
increased risk of serious infections or malignancies with DMF treatment, with the exception of progressive multifocal leukoencephalopathy cases [25]. COVID-19 occurred in
less than 1% of patients (one patient with prior
IFN treatment and two patients with prior DMF
exposure), in line with studies showing fumarate, GA, and IFN DMTs have not been associated
with
higher
risk
of
COVID-19
complications [30–32].
After up to 2 years of DRF treatment,
numerous patients in the GA/DRF and IFN/DRF
groups experienced improvements from baseline in clinical and radiological efficacy outcomes relative to prior treatment. ARR was
significantly lower with up to 2 years of DRF
treatment compared with the 12 months before
DRF (GA/DRF and IFN/DRF groups) initiation,
with similar percentage reductions in both
analysis groups and the overall population [16].
The proportion of patients with NEDA-3 was
approximately 70% at week 48 and approximately 40% after 96 weeks of therapy in

patients with prior GA or IFN treatment, rates
that are consistent with the observed 1-year and
2-year rates with DMF and DRF [16, 33, 34].
Comparisons of efficacy in patients on DMF in
EVOLVE-MS-2 versus when they were on DRF in
EVOLVE-MS-1 could not be conducted as a
result of limited exposure in EVOLVE-MS-2
(5 weeks) but the outcomes are likely to be
similar for DMF because DRF and DMF administration results in bioequivalent exposures of
the same active metabolite, MMF (Supp. Fig.)
[16]. However, if a patient wants to switch
DMTs due to a non-efficacy reason, DRF may be
an appropriate choice because of its improved
tolerability while likely maintaining efficacy.
Patients in this analysis had fewer Gd?
lesions over the 2-year study period compared
with baseline and a greater proportion were Gd?
lesion-free with DRF treatment (GA/DRF,
96.0%; IFN/DRF, 92.8%), with overall reductions similar to the observed rates in the overall
population [16]. In addition, patients treated
with DRF over 2 years showed a mean yearly
brain volume change that was similar to annualized rates of brain atrophy of - 0.27 ± 0.15%
in healthy adults (Fig. 6) [35].
Patient-centered factors are important considerations when selecting a treatment regimen,
especially addressing patient’s lifestyle, treatment burden, and interference in daily activities. In this analysis, PROs indicated that quality
of life (mobility, self-care, usual activities, pain/
discomfort,
anxiety/depression)
remained
stable over the 2-year treatment period for both

Adv Ther (2022) 39:1810–1831

analysis groups. These findings are consistent
with those of the EVOLVE-MS-1 interim analysis [16], health-related quality-of-life data
reported with other DMTs [36], and the
EVOLVE-MS-2 secondary analysis, which indicated treatment with DRF was associated with
positive quality-of-life outcomes, including
reduced effect on daily life and work and less
concomitant symptomatic medication use (e.g.,
proton pump inhibitors, anticholinergics/antispasmodics) [37].
Data from our GI tolerability analysis of
EVOLVE-MS-2 rollover patients demonstrate
that patients who switched from DMF to DRF
(DMF-rollover group) had a low incidence of
new or recurrent GI AEs with DRF over the
2-year treatment period, with rates similar to
those observed in patients treated continuously
with DRF (DRF-rollover group). However, the
most common AEs, diarrhea and nausea, were
reported with higher frequency in the DMFrollover group than in the DRF-rollover group.
Importantly, the rate of treatment discontinuation due to GI AEs was extremely low (\ 1%) in
EVOLVE-MS-2 rollover patients, regardless of
prior fumarate treatment, and was consistent
with previous studies of DRF [16, 22, 38]. For
reference, the overall rate of treatment discontinuation due to GI AEs was 0.8% (5/593) in all
fumarate-naı̈ve patients [Data on file, Biogen],
and in the EVOLVE-MS-2 study was 0.8% and
4.8% with DRF or DMF, respectively [22].
Although patients who experienced GI-related
treatment discontinuation in EVOLVE-MS-2
would not have rolled over to EVOLVE-MS-1,
overall the data indicate that transition from
DMF to DRF is a reasonable treatment strategy
associated with low rates of discontinuation.
The reported analysis is limited in that efficacy and safety outcomes could be less conclusively assessed relative to baseline because of the
open-label study design relying on retrospective
data collection of events before therapy.
Patients switching from IFN had a slightly
longer time from MS diagnosis than those who
had received other DMTs. In addition, patients
received GA, IFN, or DMF treatment for varying
durations before EVOLVE-MS-1 enrollment, and
therefore, comparisons cannot be made
between the prior treatment groups (GA/DRF
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and IFN/DRF) and the EVOLVE-MS-2 rollover
groups (DRF-rollover and DMF-rollover).
Specifically, GA/DRF and IFN/DRF patients
received GA or IFN for a median of 1.76 and
2.80 years, respectively, before initiating DRF in
EVOLVE-MS-1, whereas EVOLVE-MS-2 rollover
patients received DRF or DMF for 5 weeks after
previously being on no DMT (DRF-rollover,
33.2%; DMF-rollover, 33.9%) versus prior DMT
(DRF-rollover, 66.8%; DMF-rollover 66.1%).
Patients identified as receiving GA or IFN during
screening visit could discontinue prior therapy
and start DRF between 1 and 28 days before DRF
initiation on the basis of the investigator’s
discretion.

CONCLUSION
In this post hoc analysis, patients with RRMS
who received up to 2 years of DRF treatment
after switching from GA, IFN, or after completing EVOLVE-MS-2 had overall safety outcomes
that were consistent with previous studies of
fumarates. Notably, the rate of treatment discontinuation due to GI AEs was low (\ 1%) in
all analysis groups. Patients who switched from
GA or IFN also experienced improvements from
baseline in clinical and radiological efficacy
outcomes consistent with previous studies of
fumarates, with just under half of patients (approx. 40%) with NEDA-3 at 2 years and PBVC
approaching rates of healthy adults. Patients
switching from DMF to DRF experienced low
rates of new or recurring GI AEs. The data suggest that transition to DRF from GA, IFN, or
DMF is a reasonable treatment strategy with low
rates of discontinuation.
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